Our Technology

The SentryBond™ technology platform combines inactive excipients with active pharmaceutical ingredients in a tablet that is specifically designed to frustrate abuse via various methods of manipulation and routes of administration.  When subjected to physical manipulation and/or attempts at chemical extraction, SentryBond is designed to maintain the intended release profile of extended-release products and to delay the release of immediate release products.

Inspirion’s technology imparts its abuse-deterrent characteristics via physical and chemical methods, without the use of antagonist or aversive agents.

SentryBond technology is covered by an issued U.S. patent, with multiple U.S. and global patent applications pending.